JBIO vs PHAR
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Oct 19, 2026
JBIO
PHAR
Investment Advisor Scores
PHAR
AI Analyst Insights
Detailed Metrics Comparison
| Metric | JBIO | PHAR | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 0 | 212.766 | Tie |
| PEG Ratio | 0 | 0 | Tie |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | 0.0% | -3.2% | JBIO |
| Earnings Growth | 0.0% | -62.9% | JBIO |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 63.4/100 | 36.9/100 | JBIO |
| Profit Margin | 0.0% | 2.5% | PHAR |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | HOLD | AVOID NEW MONEY | JBIO |
Relative Price Performance (Last 90 Days)
Current Technical Phase
JBIO
NeutralMixed signals - no dominant trend phase, RSI 58
PHAR
MarkupPrice above SMA50, rising 50-day trend (1.0% over 20 days), RSI 60
Fundamentals Snapshot
| Metric | JBIO | PHAR |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | -6.1 | 70.0 |
| Trailing P/E | — | 39.4 |
| Revenue (TTM) | — | — |
| Revenue Growth | 0.0% | 0.2% |
| Gross Margin | — | 0.9% |
| Operating Margin | 0.0% | 0.1% |
| EPS | -1.92 | 0.32 |
| Dividend Yield | — | — |